Skip to content
ASCO26 Special: Assoc. Prof. Barata discusses ctDNA analysis from the KEYNOTE-564 trial episode artwork

EPISODE · Jul 7, 2026 · 12 MIN

ASCO26 Special: Assoc. Prof. Barata discusses ctDNA analysis from the KEYNOTE-564 trial

from EAU Podcast · host European Association of Urology

In this episode, UROONCO RCC chief editor Dr. Carmen Mir talks to Assoc. Prof. Pedro Barata from Case Western Reserve University, Ohio (US). They discuss the results of the ctDNA analysis in participants with renal cell carcinoma (RCC) treated with adjuvant pembrolizumab or placebo in the KEYNOTE-564 trial and the potential impact of these results for clinical practice. Read the abstract of this trial to know more. For more updates on kidney cancer, please visit our educational platform UROONCO RCC. For more EAU podcasts, please go to your favourite podcast app and subscribe to our podcast channel for regular updates: Apple Podcasts, Spotify, EAU YouTube channel.

Episode metadata supplied by the publisher feed · Published Jul 7, 2026

Embed this episode

Ready to play

ASCO26 Special: Assoc. Prof. Barata discusses ctDNA analysis from the KEYNOTE-564 trial

0:00 12:59

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

Frequently Asked Questions

How long is this episode of EAU Podcast?

This episode is 12 minutes long.

When was this EAU Podcast episode published?

This episode was published on July 7, 2026.

Can I download this EAU Podcast episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!